

## PainDetect is Copyrighted.

To access this measure, please follow these steps:

1. Fill out request form (pages 2-5 of this document)

2. Email the form to: <a href="Months:IQVIA COAs@iqvia.com">IQVIA COAs@iqvia.com</a>

## In addition:

- A Cronos licensing agreement with updated "Terms and Conditions" will be required for all licensees.
- Translation development and screen reviews will be managed by IQVIA (i.e., translation by 3rd party vendors will no longer be permitted)

Once you have the Copyright license, please share your license with <u>HEAL\_CDE@hsc.utah.edu</u> for access to the Common Data Elements for this measure.

Both English and Spanish CRFs are available.



## **REQUEST FORM**

1	Specify type of request	☐ New Instrument License		
		☐ Amendment Instrument License		
		☐ Instrument Sco	rina (IQVIA to sco	ore the completed
		instruments)	3 (	'
1a	Specify instrument for which request in	Instrument	Country	Language
	row 1 above is needed and Translations		,	3 3
	Needed			
	(please enter all that apply)			
2	Complete Name of Project Sponsor (please enter Full Legal Name)			
2a	Sponsor Company Classification (please select one)	☐ Pharmaceutica ☐ CRO ☐ For-profit Hosp ☐ For-profit Healt ☐ Other for-profit ☐ Non-profit Hosp ☐ Other non-profit ☐ Government ☐ Registered Cha ☐ Academic Univ ☐ Other (please v	ital hcare System company type (pl pital t company type (p	,
3	Project Funding Source (please enter Full Legal Name)			
3a	Project Funding Source Classification (please select one)	☐ Pharmaceutica ☐ CRO ☐ For-profit Hosp ☐ For-profit Healt ☐ Other for-profit ☐ Non-profit Hosp ☐ Other non-profit ☐ Government ☐ Registered Cha ☐ Academic Univ ☐ Other (please v	ital hcare System company type (pl pital t company type (p	please write in):
4	Full Legal Name of Company Signing the Agreement (please note the			

Version dated 25 October 2022

<sup>&</sup>quot;Copyright © 2022 IQVIA. All rights reserved. Any use, distribution or reproduction, in whole or in part, is expressly prohibited without the prior express written permission of IQVIA."



	company signing the agreement and paying for the invoice must be the same)	
5	Names of Any Third Parties Accessing/Administering/Scoring the selected instrument (please list all applicable and enter Full Legal Name for each one)	
6	Full Legal Name of Company Responsible for Compliance with Legislation on Post-marketing Safety / Pharmacovigilance and Clinical Research Guidelines (e.g., from the IRB/EC) for this Project	
7	Full Legal Name of Company that is the Marketing Authorization Holder for the Project (MOH) and is the Applicant	
8	Project Classification (please select one)	Research:    Phase   Clinical Trial   Phase   Clinical Trial   Phase   Clinical Trial   Phase   Clinical Trial   Observational (real-world) Project   Registry   Student Project   Other (please write in):   Healthcare Provider Use:   Routine Care   Other (please write in):



	9	Project Disease Area	☐ Acute Care
		•	☐ Allergy/Immunology
			□ Cardiovascular
			□ Dermatology
			□ Endocrinology
			☐ Gastrointestinal
			☐ Hematology
			☐ Hepatology
			☐ Infectious Disease
			☐ Medical Genetics
			☐ Nephrology
			☐ Neurology
			□ Oncology
			☐ Ophthalmology
			☐ Orthopedics
			☐ Psychiatry
			☐ Respiratory
			☐ Rheumatology
			☐ Transplantation
			☐ Women's Health/Sexual Health
			☐ Other (please write in):
	10	Project Primary objective	
	11	Project Secondary objective	
	12	Project Exploratory objective	
	13	Planned study endpoint for the selected	□ Primary Endpoint
		instrument	□ Secondary Endpoint
		(please select one)	□ Exploratory Endpoint
			☐ Other (please write in):
	14	Is there a study objective to assess the	☐ Yes
		psychometric properties of the selected	□ No
	15	instrument?	
	15 16	Number of Sites Number of Subjects	
	17	Age of project population	
	18	Mode of Administration	□ Paper
	. •	(please mark all that apply)	□ Electronic
		d	□ Phone
			☐ Interactive Voice Response ("IVR")
			☐ Other (please write in):
	100	If Made of Administration is Electronic	
	18a	If Mode of Administration is Electronic, on what type of device may the selected	□ Computer
		instrument be accessed? (please mark	☐ Tablet (specify all models, e.g. TABLET IPAD AIR 2):
		all that apply)	
1			☐ Smartphone (specify all models, e.g. IPHONE 6):

Version dated 25 October 2022

<sup>&</sup>quot;Copyright © 2022 IQVIA. All rights reserved. Any use, distribution or reproduction, in whole or in part, is expressly prohibited without the prior express written permission of IQVIA."



		□ BYOD (please write in which devices will be used e.g. Tablet, Smartphones, etc.): □ Other (please write in):
18b	If Mode of Administration is Electronic, who is providing the device for questionnaire completion?	☐ Patient ☐ Project Sponsor ☐ Other (please write in):
18c	If Mode of Administration is Electronic, how is the selected instrument programmed?	□ eCOA Platform (please write Full Name): □ Web Browser □ Other (please write in):
19	Name of eCOA Vendor (only if Mode of Administration = Electronic) (please mark all that apply – Please also enter Full Legal Name of the company migrating the paper COA to the electronic format if different from eCOA Vendor)	☐ Clario (ERT) ☐ IQVIA ☐ Medidata Solutions ☐ Signant Health ☐ YPrime ☐ Other (please write in):
20	Are you interested in IQVIA's eCOA platform? (only if Mode of Administration = Electronic)	
21	Number of administrations per subject	
22	Expected First Patient In Date	
23	Project End Date	
24	Have you contracted IQVIA to run any aspects of this project? If so, for which services have you contracted IQVIA (Planning, Execution/Data Collection, and/or Reporting)? Please indicate all	
25	How did you learn about the instrument?	☐ Use in previous study of ours ☐ Literature ☐ PubMed ☐ Other (please specify): ☐ IQVIA Website ☐ Word of mouth (please specify): ☐ Other (please specify):
26	Will the COA data from this project be used in a labeling claim?	☐ Yes Please specify Agency to which the labeling claim will be submitted: ☐ FDA ☐ EMA ☐ Other

Version dated 25 October 2022

<sup>&</sup>quot;Copyright © 2022 IQVIA. All rights reserved. Any use, distribution or reproduction, in whole or in part, is expressly prohibited without the prior express written permission of IQVIA."